Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival

Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival

Background: Pathologic complete response (pCR) rates in early stage HER2-positive breast cancer improved after pertuzumab was added to neoadjuvant treatment. However, survival benefit is less-well established and seems mostly limited to node-positive patients. We used national cancer registry data t...

Full description

Bibliographic Details
Main Authors: Anna van der Voort, Marte C. Liefaard, Mette S. van Ramshorst, Erik van Werkhoven, Joyce Sanders, Jelle Wesseling, Astrid Scholten, Marie Jeanne T.F.D. Vrancken Peeters, Linda de Munck, Sabine Siesling, Gabe S. Sonke
Format: Article
Language:English
Published: Elsevier 2022-10-01
Series:Breast
Subjects:
Non-metastatic breast cancer
HER2-Positive
ErbB2
Pertuzumab
Neoadjuvant chemotherapy
Survival
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977622001229

Internet

http://www.sciencedirect.com/science/article/pii/S0960977622001229

Similar Items